Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Dare Bioscience, Inc. | ceru-10q_20160630.htm |
| EX-32.2 - EX-32.2 - Dare Bioscience, Inc. | ceru-ex322_6.htm |
| EX-32.1 - EX-32.1 - Dare Bioscience, Inc. | ceru-ex321_7.htm |
| EX-31.2 - EX-31.2 - Dare Bioscience, Inc. | ceru-ex312_8.htm |
| EX-31.1 - EX-31.1 - Dare Bioscience, Inc. | ceru-ex311_9.htm |
| EX-10.2 - EX-10.2 - Dare Bioscience, Inc. | ceru-ex102_108.htm |
Exhibit 10.1
May 27, 2016
Gregg Beloff
Danforth Advisors, LLC
91 Middle Road
Southborough, MA
01772
Dear Gregg:
This letter is in reference to the Consulting Agreement between Cerulean Pharma Inc. ("Cerulean") and Danforth Advisors, LLC dated May 27, 2015 (the "Agreement"). Capitalized terms used herein and not otherwise defined shall have the meaning given such terms in the Agreement.
As Cerulean desires your continued services, you and Cerulean hereby agree to an extension of the term of the Agreement through May 26, 2017.
If this extension meets with your approval, please countersign a copy of this letter and return one copy to the undersigned.
Very truly yours,
CERULEAN PHARMA INC.
|
By: |
/s/ Christopher D. T. Guiffre |
|
|
Christopher D. T. Guiffre |
|
|
President & CEO |
Agreed to:
DANFORTH ADVISORS, LLC
|
By: |
/s/ Gregg Beloff |
|
|
Gregg Beloff |
|
|
Managing Director |
Cerulean Pharma Inc. | 35 Gatehouse Drive I Waltham, MA 02451 1 P: 781-996-4300 1 F: 844-894-2378